|
See related NuvaRing vag ring information |
|
|
|
Manufacturer |
NV Organon |
|
Distributor |
Zuellig |
|
Contents |
Etonogestrel 0.12 mg, ethinylestradiol 0.015 mg per 24 hr |
|
Indications |
Contraception. |
|
Dosage |
Insert 1 ring into the vagina on the 1st day of menstruation. Leave the ring in place for 3 wk. Insert a new ring 1 wk after removal of the previous ring. |
|
Contraindications |
Venous thrombosis or thromboembolic events w/ or w/o pulmonary embolism. Arterial thrombosis (eg CVA, MI) or prodromi of a thrombosis (eg angina pectoris or transient ischaemic attack). Activated protein C resistance, antithrombin-III deficiency, protein C or S deficiency, hyperhomocysteinemia & antiphospholipid Abs (anticardiolipin Abs, lupus anticoagulant). History of migraine w/ focal neurological symptoms, DM w/ vascular involvement, pancreatitis associated w/ severe hypertriglyceridemia. Severe hepatic disease, liver tumors. Risk factors for venous or arterial thrombosis. Known or suspected malignant conditions of genital organs or the breast. Undiagnosed vag bleeding. Pregnancy. |
|
Special Precautions |
Increased risk of venous or arterial thromboembolism. SLE, hemolytic uremic syndrome, chronic inflammatory bowel disease, sickle cell disease. Increased risk of pancreatitis in women w/ hypertriglyceridemia. Hepatic impairment, history of chloasma gravidarum. Lactation. |
|
Adverse Drug Reactions |
Vag infection, depression, decreased libido, headache, migraine, abdominal pain, nausea, acne, breast tenderness, female genital pruritus, dysmenorrhoea, pelvic pain, vag discharge, increased wt, medical device discomfort.
View ADR Monitoring Form |
|
Drug Interactions |
Phenytoin, phenobarb, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin, St. John's wort, penicillins, tetracyclines, ciclosporin, lamotrigine.
View more drug interactions with NuvaRing |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
NuvaRing vaginal ring |
|
|
|
Manufacturer: |
NV Organon |
|
Distributor: |
Zuellig |
|
Marketer: |
MSD
|
|
|
|
